Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular, Intranasal or Inhaled Administration in Healthy Volunteers

NCT04839042 is registered in ClinicalTrials.gov with Moat Biotechnology Corporation as lead sponsor.

NCT NCT04839042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04839042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular, Intranasal or Inhaled Administration in Healthy Volunteers
Lead sponsor
Moat Biotechnology Corporation
Phase
Phase 1
Overall status
Completed
Start date
June 28, 2021
Completion date
March 4, 2025
Enrollment
196 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19